MedCity News
Biotech IPO wave rolls on as Werewolf, Vaccitech raise $230M for clinical trials
Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines.
Shares0
Two more biotech companies are joining the public markets. Werewolf Therapeutics and Vaccitech priced their respective IPOs late Thursday, raising a combined $230 million for multiple clinical trials.
Werewolf was able to boost the size of its deal, selling 7.5 million shares, up from the 6.25 million shares that it had initially planned to offer. Those shares were priced at $16 each, right at the midpoint of the biotech’s projected price range, and the company was able to gross $120 million. Werewolf’s shares will trade on the Nasdaq under the stock symbol “HOWL.”
The week s good news: April 29, 2021 Catherine Garcia
1.
On Brett Wittwer s last day at work before retiring, the tables were turned. Wittwer, 69, spent 35 years as a U.S. Postal Service mail carrier, and was used to handing people packages. But on March 26, residents along his mail route were giving
him gift bags and boxes filled with goodies. It was crazy, Wittwer told
Good Morning America. It kind of brings a tear to your eye. Most of his career was spent delivering mail in the Cincinnati area, and when word spread he was going to retire, people along his route used a neighborhood Facebook page to plan a surprise sendoff. They decorated their mailboxes with balloons, and filled them with presents and notes of appreciation. Waiting for him at the end of his route were several neighbors, standing under a Happy Retirement banner. The sign was made by Glenna Weber Stricklett, who told
Breakthrough Oxford malaria vaccine shows record efficacy in early trial
By Kezia Parkins 28 Apr 2021 (Last Updated April 28th, 2021 16:53)
A new vaccine against malaria, one of the world’s leading causes of child mortality, could be on the horizon as scientists at the University of Oxford’s Jenner Institute announce that their candidate achieved 77% efficacy in early stage trials – making it the first malaria vaccine to meet the WHO’s target of 75%.
A malaria vaccine developed by scientists at the University of Oxford’s Jenner Institute is being hailed as a breakthrough as early trials show efficacy of 77%.
Image Credit: Shutterstock
New Malaria Vaccine Shows Most Efficacy of Any to Date: Small Trial the-scientist.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from the-scientist.com Daily Mail and Mail on Sunday newspapers.